- Home
- Publications
- Publication Search
- Publication Details
Title
New perspectives of valproic acid in clinical practice
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 12, Pages 1535-1547
Publisher
Informa Healthcare
Online
2013-10-28
DOI
10.1517/13543784.2013.853037
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II
- (2013) Cheguo Tsai et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
- (2013) Gerald S. Falchook et al. INVESTIGATIONAL NEW DRUGS
- Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism
- (2013) Jakob Christensen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma
- (2013) Jonas de Jonge et al. JOURNAL OF GENE MEDICINE
- A proapoptotic effect of valproic acid on progenitors of embryonic stem cell-derived glutamatergic neurons
- (2013) R Fujiki et al. Cell Death & Disease
- Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer
- (2012) Himashinie V.K. Diyabalanage et al. CANCER LETTERS
- The Teratogenic Potencies of Valproic Acid Derivatives and Their Effects on Biological End-points are Related to Changes in Histone Deacetylase and Erk1/2 Activities
- (2011) Kamil Gotfryd et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Intrinsic Anticancer Drug Resistance of Malignant Melanoma Cells Is Abrogated by IFN- and Valproic Acid
- (2011) W. P. Roos et al. CANCER RESEARCH
- Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL
- (2011) Vitaliy O. Kaminskyy et al. CARCINOGENESIS
- Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination
- (2011) Miglena Koprinarova et al. DNA REPAIR
- Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue
- (2011) Tawfeeq Shekh-Ahmad et al. EPILEPSY RESEARCH
- Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
- (2011) Jacob E. Shabason et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
- (2011) Andrea Kuendgen et al. Clinical Epigenetics
- Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial
- (2010) Myrna Candelaria et al. ANNALS OF HEMATOLOGY
- Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation
- (2010) Kamil Gotfryd et al. BMC CANCER
- Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
- (2010) Ya-Li Yao et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells
- (2010) L Bastian et al. LEUKEMIA
- Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy
- (2010) G J Leclerc et al. LEUKEMIA
- HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells
- (2009) Xufeng Chen et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr−/− murine model of autoimmune lymphoproliferative syndrome (ALPS)
- (2009) Kennichi C. Dowdell et al. EXPERIMENTAL HEMATOLOGY
- Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs
- (2009) Kimford J. Meador et al. NEW ENGLAND JOURNAL OF MEDICINE
- Valproic acid in pregnancy: How much are we endangering the embryo and fetus?
- (2009) Asher Ornoy REPRODUCTIVE TOXICOLOGY
- Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
- (2008) Nagma Khan et al. BIOCHEMICAL JOURNAL
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice
- (2008) Li-Kai Tsai et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Histone acetylation resulting in resistance to methotrexate in choroid plexus cells
- (2008) Preethi Prasad et al. JOURNAL OF NEURO-ONCOLOGY
- Chronic Administration of Valproic Acid Reduces Brain NMDA Signaling via Arachidonic Acid in Unanesthetized Rats
- (2008) Mireille Basselin et al. NEUROCHEMICAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started